Okada N - Search Results

1

A complement-dependent cytotoxicity-enhancing anti-CD20 antibody mediating potent antitumor activity in the humanized NOD/Shi-scid, IL-2Rγ(null) mouse lymphoma model.

Sato F, Ito A, Ishida T, Mori F, Takino H, Inagaki A, Ri M, Kusumoto S, Komatsu H, Iida S, Okada N, Inagaki H, Ueda R. Sato F, et al. Among authors: okada n. Cancer Immunol Immunother. 2010 Dec;59(12):1791-800. doi: 10.1007/s00262-010-0905-2. Epub 2010 Aug 17. Cancer Immunol Immunother. 2010. PMID: 20714721 Free PMC article.

2

The CC chemokine receptor 4 as a novel specific molecular target for immunotherapy in adult T-Cell leukemia/lymphoma.

Ishida T, Iida S, Akatsuka Y, Ishii T, Miyazaki M, Komatsu H, Inagaki H, Okada N, Fujita T, Shitara K, Akinaga S, Takahashi T, Utsunomiya A, Ueda R. Ishida T, et al. Among authors: okada n. Clin Cancer Res. 2004 Nov 15;10(22):7529-39. doi: 10.1158/1078-0432.CCR-04-0983. Clin Cancer Res. 2004. PMID: 15569983

3

Chimeric human/murine monoclonal IgM antibodies to HIV-1 Nef antigen expressed on chronically infected cells.

Kawai M, He L, Kawamura T, Omoto S, Fujii YR, Okada N. Kawai M, et al. Among authors: okada n. Microbiol Immunol. 2003;47(3):247-53. doi: 10.1111/j.1348-0421.2003.tb03384.x. Microbiol Immunol. 2003. PMID: 12725296 Free article.

4

Human IgM monoclonal antibodies reactive with HIV-1-infected cells generated using a trans-chromosome mouse.

Okada N, Yin S, Asai S, Kimbara N, Dohi N, Hosokawa M, Wu X, Okada H. Okada N, et al. Among authors: okada h. Microbiol Immunol. 2005;49(5):447-59. doi: 10.1111/j.1348-0421.2005.tb03749.x. Microbiol Immunol. 2005. PMID: 15905607 Free article.

5

Mouse complement receptor-related gene y/p65-neutralized tumor vaccine induces antitumor activity in vivo.

Ohta R, Kondor N, Dohi N, Tomlinson S, Imai M, Holers VM, Okada H, Okada N. Ohta R, et al. Among authors: okada n, okada h. J Immunol. 2004 Jul 1;173(1):205-13. doi: 10.4049/jimmunol.173.1.205. J Immunol. 2004. PMID: 15210776

6

Inhibition of a complement regulator in vivo enhances antibody therapy in a model of mammary adenocarcinoma.

Imai M, Ohta R, Okada N, Tomlinson S. Imai M, et al. Among authors: okada n. Int J Cancer. 2004 Jul 20;110(6):875-81. doi: 10.1002/ijc.20178. Int J Cancer. 2004. PMID: 15170670

7

Soluble complement receptor type 1 protects rats from lethal shock induced by anti-Crry antibody following lipopolysaccharide priming.

Mizuno M, Nishikawa K, Okada N, Matsuo S, Okada H. Mizuno M, et al. Among authors: okada n, okada h. Int Arch Allergy Immunol. 2002 Jan;127(1):55-62. doi: 10.1159/000048169. Int Arch Allergy Immunol. 2002. PMID: 11893854

8

A tumor-expressed inhibitor of the early but not late complement lytic pathway enhances tumor growth in a rat model of human breast cancer.

Caragine TA, Okada N, Frey AB, Tomlinson S. Caragine TA, et al. Among authors: okada n. Cancer Res. 2002 Feb 15;62(4):1110-5. Cancer Res. 2002. PMID: 11861390

9

Membrane complement regulators protect against fibrin exudation increases in a severe peritoneal inflammation model in rats.

Mizuno M, Ito Y, Mizuno T, Harris CL, Suzuki Y, Okada N, Matsuo S, Morgan BP. Mizuno M, et al. Among authors: okada n. Am J Physiol Renal Physiol. 2012 May 15;302(10):F1245-51. doi: 10.1152/ajprenal.00652.2011. Epub 2012 Feb 15. Am J Physiol Renal Physiol. 2012. PMID: 22338087 Free article.

10

Diagnostic surface expression of SWAP-70 on HIV-1 infected T cells.

Kimbara N, Dohi N, Miyamoto M, Asai S, Okada H, Okada N. Kimbara N, et al. Among authors: okada n, okada h. Microbiol Immunol. 2006;50(3):235-42. doi: 10.1111/j.1348-0421.2006.tb03790.x. Microbiol Immunol. 2006. PMID: 16547421 Free article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

1,969 results

Search Page

Filters